Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer

NCT05483868 is registered in ClinicalTrials.gov with Aura Biosciences as lead sponsor.

NCT NCT05483868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05483868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer
Lead sponsor
Aura Biosciences
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 26, 2022
Completion date
March 31, 2027
Enrollment
55 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

nmibc, non-muscle invasive bladder carcinoma, non-muscle invasive bladder neoplasms, non-muscle invasive bladder urothelial carcinoma, non-muscle-invasive bladder cancer, urothelial carcinoma bladder